Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.93)
# 1,539
Out of 4,964 analysts
72
Total ratings
39.47%
Success rate
1.64%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Reiterates: Buy | $18 | $8.84 | +103.62% | 2 | Aug 25, 2025 | |
| DERM Journey Medical | Initiates: Buy | $13 | $7.24 | +79.56% | 2 | Aug 25, 2025 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.16 | +279.75% | 2 | Aug 21, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $5.27 | +127.71% | 3 | Aug 20, 2025 | |
| GNFT Genfit | Assumes: Buy | $9 | $4.06 | +121.57% | 1 | Aug 19, 2025 | |
| PYPD PolyPid | Reiterates: Buy | $13 | $3.39 | +283.48% | 4 | Aug 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $7 | $1.77 | +295.48% | 2 | Aug 13, 2025 | |
| XERS Xeris Biopharma Holdings | Assumes: Buy | $10 | $7.90 | +26.58% | 1 | Aug 12, 2025 | |
| COLL Collegium Pharmaceutical | Assumes: Buy | $44 | $38.35 | +14.73% | 6 | Aug 11, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $84 → $93 | $92.53 | +0.51% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $14.35 | +18.47% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $7.56 | +283.85% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $23.88 | +17.25% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $8.69 | +130.15% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $4.49 | +100.45% | 3 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.30 | +179.57% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.39 | +331.65% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $1.81 | +176.24% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.09 | +725.69% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.21 | +191.26% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.80 | +177.78% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.23 | +112.77% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.39 | +1,957.61% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.39 | +90.70% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.54 | +1,752.54% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $18.23 | +2,395.89% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $33.73 | +74.92% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $126.13 | +42.71% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $3.37 | +6,428.19% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $28.93 | +10.61% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.32 | +1,666,566.67% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $15.52 | +222.16% | 1 | Jul 12, 2018 |
Valneva SE
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $8.84
Upside: +103.62%
Journey Medical
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $7.24
Upside: +79.56%
Achieve Life Sciences
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $3.16
Upside: +279.75%
Eupraxia Pharmaceuticals
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $5.27
Upside: +127.71%
Genfit
Aug 19, 2025
Assumes: Buy
Price Target: $9
Current: $4.06
Upside: +121.57%
PolyPid
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.39
Upside: +283.48%
Connect Biopharma Holdings
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $1.77
Upside: +295.48%
Xeris Biopharma Holdings
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $7.90
Upside: +26.58%
Collegium Pharmaceutical
Aug 11, 2025
Assumes: Buy
Price Target: $44
Current: $38.35
Upside: +14.73%
ANI Pharmaceuticals
Aug 8, 2025
Maintains: Buy
Price Target: $84 → $93
Current: $92.53
Upside: +0.51%
Aug 8, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $14.35
Upside: +18.47%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $7.56
Upside: +283.85%
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $23.88
Upside: +17.25%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $8.69
Upside: +130.15%
Jul 25, 2025
Reiterates: Buy
Price Target: $9
Current: $4.49
Upside: +100.45%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.30
Upside: +179.57%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.39
Upside: +331.65%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.81
Upside: +176.24%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.09
Upside: +725.69%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $7.21
Upside: +191.26%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.80
Upside: +177.78%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $4.23
Upside: +112.77%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.39
Upside: +1,957.61%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.39
Upside: +90.70%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.54
Upside: +1,752.54%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $18.23
Upside: +2,395.89%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $33.73
Upside: +74.92%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $126.13
Upside: +42.71%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $3.37
Upside: +6,428.19%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $28.93
Upside: +10.61%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.32
Upside: +1,666,566.67%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $15.52
Upside: +222.16%